Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists
Authors:
Open Access
- 14 July 2015
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (9) , 1590-1596
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Dabigatran and Postmarketing Reports of BleedingNew England Journal of Medicine, 2013
- Hemorrhagic Complications in Emergency Department Patients Who Are Receiving Dabigatran Compared With WarfarinAnnals of Emergency Medicine, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Oral Anticoagulant TherapyChest, 2012
- RivaroxabanClinical Pharmacokinetics, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- How to prevent, treat, and overcome current clinical challenges of VTEJournal of Thrombosis and Haemostasis, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005